FDA clears updated Pfizer and Moderna COVID vaccines for the 2026-27 season

The U.S. Food and Drug Administration approved updated COVID-19 vaccines from PFE and MRNA for the 2026-27 season, a clearance both manufacturers confirmed. Moderna's approval for its updated formulation was reported separately.

The mechanics matter more than the headline. These are antigenic updates rather than new products, matched to the SARS-CoV-2 variants expected to circulate this season, and the process now mirrors the annual influenza model. For both companies the approval is what makes the season's revenue possible at all, so a timely clearance is a schedule risk removed rather than upside created.

The commercial question sitting behind it is uptake, not approval. COVID vaccination volumes have fallen well below their pandemic peaks, and the season's economics now depend on co-administration with flu shots, pharmacy channel access and whatever recommendation framework accompanies the clearance. None of that is settled by the FDA decision itself.

SentiSense has Moderna at $136.50, down 4.4% on the session, even though its score sits at Strong Bullish with a 30-day average of 25.7 and a latest reading of 42.5, and it ranks 18th on social dominance. Moderna has drawn three analyst rating actions in the last seven days, one of them an upgrade. What to watch is the recommendation and reimbursement guidance that follows, plus early pharmacy uptake data, since those determine whether this season's franchise holds or shrinks again.

Related Stocks

• MRNA
• PFE